177 related articles for article (PubMed ID: 23883485)
1. Kampo formulations, chotosan, and yokukansan, for dementia therapy: existing clinical and preclinical evidence.
Matsumoto K; Zhao Q; Niu Y; Fujiwara H; Tanaka K; Sasaki-Hamada S; Oka J
J Pharmacol Sci; 2013; 122(4):257-69. PubMed ID: 23883485
[TBL] [Abstract][Full Text] [Related]
2. Neuropharmacological efficacy of the traditional Japanese Kampo medicine yokukansan and its active ingredients.
Ikarashi Y; Mizoguchi K
Pharmacol Ther; 2016 Oct; 166():84-95. PubMed ID: 27373856
[TBL] [Abstract][Full Text] [Related]
3. Daily administration of yokukansan and keishito prevents social isolation-induced behavioral abnormalities and down-regulation of phosphorylation of neuroplasticity-related signaling molecules in mice.
Fujiwara H; Han Y; Ebihara K; Awale S; Araki R; Yabe T; Matsumoto K
BMC Complement Altern Med; 2017 Apr; 17(1):195. PubMed ID: 28376888
[TBL] [Abstract][Full Text] [Related]
4. Yokukansan Ameliorates Hippocampus-Dependent Learning Impairment in Senescence-Accelerated Mouse.
Azuma K; Toyama T; Katano M; Kajimoto K; Hayashi S; Suzuki A; Tsugane H; Iinuma M; Kubo KY
Biol Pharm Bull; 2018; 41(10):1593-1599. PubMed ID: 30270329
[TBL] [Abstract][Full Text] [Related]
5. Ameliorative effects of yokukansan on learning and memory deficits in olfactory bulbectomized mice.
Yamada M; Hayashida M; Zhao Q; Shibahara N; Tanaka K; Miyata T; Matsumoto K
J Ethnopharmacol; 2011 Jun; 135(3):737-46. PubMed ID: 21513784
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of Active Components of Yokukansan, a Traditional Japanese Herbal Medicine after a Single Oral Administration to Healthy Japanese Volunteers: A Cross-Over, Randomized Study.
Kitagawa H; Munekage M; Ichikawa K; Fukudome I; Munekage E; Takezaki Y; Matsumoto T; Igarashi Y; Hanyu H; Hanazaki K
PLoS One; 2015; 10(7):e0131165. PubMed ID: 26151135
[TBL] [Abstract][Full Text] [Related]
7. Glycyrrhiza and Uncaria Hook contribute to protective effect of traditional Japanese medicine yokukansan against amyloid β oligomer-induced neuronal death.
Kanno H; Kawakami Z; Iizuka S; Tabuchi M; Mizoguchi K; Ikarashi Y; Kase Y
J Ethnopharmacol; 2013 Aug; 149(1):360-70. PubMed ID: 23838475
[TBL] [Abstract][Full Text] [Related]
8. Chotosan, a Kampo formula, ameliorates hippocampal LTD and cognitive deficits in juvenile-onset diabetes rats.
Sasaki-Hamada S; Tamaki K; Otsuka H; Ueno T; Sacai H; Niu Y; Matsumoto K; Oka J
J Pharmacol Sci; 2014; 124(2):192-200. PubMed ID: 24476927
[TBL] [Abstract][Full Text] [Related]
9. Ameliorative effect of traditional Japanese medicine yokukansan on age-related impairments of working memory and reversal learning in rats.
Mizoguchi K; Shoji H; Tanaka Y; Tabira T
Neuroscience; 2011 Mar; 177():127-37. PubMed ID: 21195139
[TBL] [Abstract][Full Text] [Related]
10. Basic Study of Drug-Drug Interaction between Memantine and the Traditional Japanese Kampo Medicine Yokukansan.
Matsumoto T; Sekiguchi K; Kawakami Z; Watanabe J; Mizoguchi K; Ikarashi Y; Yamamoto M
Molecules; 2018 Dec; 24(1):. PubMed ID: 30597998
[TBL] [Abstract][Full Text] [Related]
11. Effect of yokukansan on the behavioral and psychological symptoms of dementia in elderly patients with Alzheimer's disease.
Monji A; Takita M; Samejima T; Takaishi T; Hashimoto K; Matsunaga H; Oda M; Sumida Y; Mizoguchi Y; Kato T; Horikawa H; Kanba S
Prog Neuropsychopharmacol Biol Psychiatry; 2009 Mar; 33(2):308-11. PubMed ID: 19138715
[TBL] [Abstract][Full Text] [Related]
12. Effects of Yokukansan on behavioral and psychological symptoms of dementia in regular treatment for Alzheimer's disease.
Okahara K; Ishida Y; Hayashi Y; Inoue T; Tsuruta K; Takeuchi K; Yoshimuta H; Kiue K; Ninomiya Y; Kawano J; Yoshida K; Noda S; Tomita S; Fujimoto M; Hosomi J; Mitsuyama Y
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Apr; 34(3):532-6. PubMed ID: 20170698
[TBL] [Abstract][Full Text] [Related]
13. Repeated administration of Yokukansan inhibits DOI-induced head-twitch response and decreases expression of 5-hydroxytryptamine (5-HT)2A receptors in the prefrontal cortex.
Egashira N; Iwasaki K; Ishibashi A; Hayakawa K; Okuno R; Abe M; Uchida N; Mishima K; Takasaki K; Nishimura R; Oishi R; Fujiwara M
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1516-20. PubMed ID: 18558456
[TBL] [Abstract][Full Text] [Related]
14. Anxiolytic effect of a herbal medicine, yokukansan, in aged rats: involvement of serotonergic and dopaminergic transmissions in the prefrontal cortex.
Mizoguchi K; Tanaka Y; Tabira T
J Ethnopharmacol; 2010 Jan; 127(1):70-6. PubMed ID: 19799980
[TBL] [Abstract][Full Text] [Related]
15. Randomized double-blind placebo-controlled multicenter trial of Yokukansan for neuropsychiatric symptoms in Alzheimer's disease.
Furukawa K; Tomita N; Uematsu D; Okahara K; Shimada H; Ikeda M; Matsui T; Kozaki K; Fujii M; Ogawa T; Umegaki H; Urakami K; Nomura H; Kobayashi N; Nakanishi A; Washimi Y; Yonezawa H; Takahashi S; Kubota M; Wakutani Y; Ito D; Sasaki T; Matsubara E; Une K; Ishiki A; Yahagi Y; Shoji M; Sato H; Terayama Y; Kuzuya M; Araki N; Kodama M; Yamaguchi T; Arai H
Geriatr Gerontol Int; 2017 Feb; 17(2):211-218. PubMed ID: 26711658
[TBL] [Abstract][Full Text] [Related]
16. Yokukansan in the Treatment of Behavioral and Psychological Symptoms of Dementia: An Updated Meta-Analysis of Randomized Controlled Trials.
Matsunaga S; Kishi T; Iwata N
J Alzheimers Dis; 2016 Sep; 54(2):635-43. PubMed ID: 27497482
[TBL] [Abstract][Full Text] [Related]
17. Chotosan ameliorates cognitive and emotional deficits in an animal model of type 2 diabetes: possible involvement of cholinergic and VEGF/PDGF mechanisms in the brain.
Zhao Q; Niu Y; Matsumoto K; Tsuneyama K; Tanaka K; Miyata T; Yokozawa T
BMC Complement Altern Med; 2012 Oct; 12():188. PubMed ID: 23082896
[TBL] [Abstract][Full Text] [Related]
18. Multiple Psychopharmacological Effects of the Traditional Japanese Kampo Medicine Yokukansan, and the Brain Regions it Affects.
Mizoguchi K; Ikarashi Y
Front Pharmacol; 2017; 8():149. PubMed ID: 28377723
[TBL] [Abstract][Full Text] [Related]
19. Effects of Yokukansan, a Japanese Kampo Medicine for Symptoms Associated Autism Spectrum Disorder.
Wake R; Miyaoka T; Furuya M; Hashioka S; Horiguchi J
CNS Neurol Disord Drug Targets; 2016; 15(5):551-63. PubMed ID: 27071791
[TBL] [Abstract][Full Text] [Related]
20. Yokukansan inhibits social isolation-induced aggression and methamphetamine-induced hyperlocomotion in rodents.
Uchida N; Egashira N; Iwasaki K; Ishibashi A; Tashiro R; Nogami A; Manome N; Abe M; Takasaki K; Mishima K; Takata J; Oishi R; Nishimura R; Fujiwara M
Biol Pharm Bull; 2009 Mar; 32(3):372-5. PubMed ID: 19252280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
